Black Diamond Therapeutics Q3 2026 net loss widens 18% to $10 million
BDTX•Black Diamond Therapeutics’ third-quarter 2026 net loss widened 18% year over year to $10 million. The company reported $102 million in cash, cash equivalents and investments, and said its funding is expected to last into the second half of 2028.
1. Quarterly results
General and administrative expenses rose 46% year over year to $5.1 million, due to higher IP-related costs and non-income tax expense. Cash, cash equivalents and investments totaled $102 million at September 30, 2026, with expected funding into the second half of 2028.
2. Silevertinib trial
Silevertinib’s Phase 2 trial showed an 86% CNS response rate in evaluable patients with untreated brain metastases. Following FDA feedback, a Phase 3 trial could begin in the second quarter of 2027, with a potential accelerated approval pathway.
